Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disorder and primarily arises from mutations in either the polycystic kidney disease 1 (PKD1) or 2 (PKD2) gene. Although traditionally categorized as an adult-onset disease, cystogenesis often begins in utero, and structural changes may become evident during childhood. Although most pediatric patients with ADPKD remain asymptomatic, hypertension occurs in 20%–40% of cases, and albuminuria may also be present. Both findings represent early, treatable manifestations that can significantly influence long-term prognosis. Ultrasonography is the preferred diagnostic modality; however, genetic testing is indicated in very-early-onset or atypical cases. The cornerstone of disease management is rigorous blood pressure control using renin–angiotensin system inhibitors, along with lifestyle modifications such as sodium restriction and adequate hydration. Early diagnosis and intervention are essential for optimizing long-term clinical outcomes in pediatric patients with ADPKD. This study aimed to provide a comprehensive review of the genetics, pathophysiology, clinical manifestations, diagnosis, treatment, and future management of pediatric ADPKD.
Mun et al. (Fri,) studied this question.